ctDNA May Replace Bone Marrow Exams in Multiple Myeloma, Expert SaysFebruary 23rd 2023
An expert from Stanford Medicine that the goal behind a study characterizing circulating tumor DNA and its predictive value is to eventually replace blood marrow exams with a blood draw for those with multiple myeloma.
Panobinostat Regimen Yields Benefit for R/R Myeloma After Frontline ASCTFebruary 23rd 2023
Evidence from a matched pair comparison with a concurrent control cohort suggests that panobinostat plus gemcitabine, busulfan, and melphalan improves progression-free survival in those with relapsed or refractory multiple myeloma, especially after first transplant.
NALIRIFOX Demonstrates Consistent Safety in Metastatic Pancreatic CancerFebruary 19th 2023
Patients with metastatic pancreatic ductal adenocarcinoma who receive NALIRIFOX tend to have more gastrointestinal toxicity while nab-paclitaxel/gemcitabine results in more cytopenias, according to an expert from University of California, Los Angeles.